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MaUp to 20% of all coronary angiograms reveal coronary chronic total occlusions (CTOs). The lack of robust type A evidence
with hard clinical outcomes on the beneﬁts of CTO revascularization has hampered attempts to develop recommenda-
tions regarding the optimal management of CTOs. This review presents issues surrounding CTO revascularization within
the framework of the appropriate use criteria ratings. Appropriate use criteria ratings downgrade CTO percutaneous
coronary intervention revascularization relative to non-CTOs and to surgical revascularization. Speciﬁc aspects of CTO
revascularization include ischemic burden, impact of revascularization on quality of life, risks in CTO revascularization,
and the importance of complete revascularization. Contemporary data suggest CTO revascularization may have sub-
stantial impact on patient outcomes; thus, revascularization should likely be held to similar criteria as nonocclusive
lesions. However, additional large clinical trial data are required to more deﬁnitively determine CTO revascularization
guidelines. (J Am Coll Cardiol 2014;64:1281–9) © 2014 by the American College of Cardiology Foundation.C oronary chronic total occlusions (CTOs), adistinct subset of coronary artery disease(CAD), are deﬁned on invasive angiography
as coronary arteries with either absent or minimal
anterograde blood ﬂow for >12 weeks duration. In
recent years, coronary CTO management has become
increasingly important in routine practice and a focus
for pre-clinical and clinical research (1–3). This inter-
est is stimulated by the prevalence of CTOs (nearly
20% of all coronary angiograms) (4); yet, there is a
paucity of data on how best to manage the need for
revascularization and the preferred modality (coro-
nary artery bypass grafting surgery [CABG] or percu-
taneous coronary intervention [PCI]).
Critics of CTO revascularization generally perceive
that symptoms are rare and are easily controlled by
medications and that revascularization frequently
supplies infarcted left ventricular (LV) myocardium
that would not beneﬁt. Empirically, physicians treatm the Schulich Heart Center, Sunnybrook Health Sciences Center, Univers
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evident from relatively low rates of overall revascu-
larization compared with medical therapy and sub-
stantially less PCI than CABG. Only approximately
35% of CTOs are currently treated by revasculariza-
tion (either CABG or PCI) (4). In CTO patients, only
about one-third of PCI attempts are directed toward
the CTO artery; non-CTO arteries are preferentially
targeted (4). In these multivessel CTO patients, sur-
gical revascularization of the CTO artery is variable,
with published reports ranging from 69% to 89%
(4,5). For CTO patients who had a revascularization
strategy recommended, CABG is the mainstay by a
nearly 3:1 ratio (4). In contrast, observational studies
suggest that approximately 60% of patients with
nonocclusive chronic stable ischemic disease undergo
revascularization, with PCI as the modality almost
twice as often. This review examines the rationale for
this distinct treatment of CTO lesions, concentratingity of Toronto, Toronto, Ontario, Canada. Dr. Strauss
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1282on 2 key clinical decision points: ﬁrst,
whether to revascularize; and second, which
modality. We hope to provide a framework to
facilitate discussion between physicians and
patients and to improve decision-making for
these complex patients.
REVASCULARIZATION DECISION
MAKING IN CAD WITH CTO
To facilitate clinical decision-making, an
expert panel representing the views of
major American cardiovascular organizations
developed appropriate use criteria (AUC). A
formal document outlining 180 clinical sce-
narios graded by whether revascularization
was appropriate, uncertain, or inappropriatewas initially published in 2009 (6), and most recently
updated in 2012 (7). According to the AUC’s concep-
tual framework, a revascularization procedure would
be considered appropriate if its expected beneﬁts in
terms of survival or health outcomes (symptoms,
functional status, and/or quality of life [QOL]) exceed
its expected risks by a sufﬁciently widemargin (7). The
AUC classiﬁes patients on the basis of symptomppropriate Use Rating in CTOs and in Non-CTOs in
-vessel disease chronic total occlusions (CTOs) and in non-
nd risk in noninvasive study. Differences in recommen-
-CTOs are labeled with red circles. A ¼ appropriate;
. 1-VD ¼ single vessel disease. Adapted with permissionseverity, ﬁndings on pre-procedural stress testing, and
anatomic location and extent of coronary stenosis. The
only modiﬁer of coronary anatomy included in the
current AUC is the lesion being a CTO; other forms of
anatomic complexity are not considered. The implicit
assumption is that for the same lesion location,
symptom severity, and ischemic burden, a CTO differs
from a non-CTO, either due to the perceived beneﬁt of
revascularization or the harm of the procedure.Wewill
examine this rationale in detail.
There are 2 broad clinical revascularization sce-
narios involving CTOs: isolated CTOs or multivessel
disease.
ISOLATED (“LONE”) CTO
Clinical indications 23 to 27 speciﬁcally approach
single-vessel CTOs, making different recommenda-
tions for CTO and nonocclusive lesions (Central
Illustration) for the same symptom severity, lesion
location, extent of ischemia, and intensity of medi-
cations (7). In several scenarios, CTO revasculariza-
tion is downgraded compared with non-CTO vessels
(“uncertain” in CTO from “appropriate” in non-CTO,
and “inappropriate” in CTO from “uncertain” in
non-CTO), supporting a more conservative approach
to revascularization of CTOs relative to non-CTOs.
The document does not clearly state why CTO re-
vascularization was discouraged. However, the con-
ceptual framework presented earlier suggests that the
rationale is the elevated risk due to the procedure’s
complexity, balanced against their uncertain beneﬁts.
Several points should inform this decision as to
whether CTOs should be considered separately from
non-CTOs in revascularization decisions:
DO PATIENTS WITH CTO HAVE ISCHEMIA? The AUC
heavily emphasize ischemic burden and suggest that
revascularization is appropriate in cases with large
territories of ischemia, even without symptoms. It is
important to dismiss the common misconception that
CTOs overwhelmingly supply infarcted myocardial
territories not prone to ischemia. In the Canadian
CTO registry, LV function was normal (grade 1) in
50% of patients, and only 17% had signiﬁcantly
reduced LV function (grade 3 to 4), with electrocar-
diographic evidence of infarction in only one-third of
patients (4).
The evaluation of myocardial ischemia can be
challenging (8); indeed, invasive assessment of is-
chemia through fractional ﬂow reserve (FFR) is
increasingly preferred, given studies showing clinical
beneﬁt with revascularization decisions on the basis
of FFR results (9). Using FFR, Sachdeva et al. (10)
showed that every CTO evaluated in their series was
TABLE 1 CTO Revascularization in Canadian CTO Registry
According to Number of Diseased Vessels
1 VD
(n ¼ 225)
2 VD
(n ¼ 297)
3 VD
(n ¼ 1,019)
LM
(n ¼ 127)
Medical 72 46 46 20
PCI 21 41 26 6
CABG 5 11 27 72
PCI þ CABG 2 2 1 2
CTO intervention
PCI to CTO 21 12 7 2
CABG to CTO 5 10 22 54
Values are %.
CABG ¼ coronary artery bypass graft; CTO ¼ chronic total occlusion; LM ¼ left
main; PCI ¼ percutaneous coronary intervention; VD ¼ vessel disease.
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1283hemodynamically signiﬁcant, even in the presence
of extensive collateralization and/or with regional
LV dysfunction. Furthermore, resting ischemia was
present in 78% of CTO patients, evidenced by a
resting Pd/Pa <0.80 (Pd ¼ pressure distal to the
lesion, Pa ¼ pressure proximal to the lesion) (10).
This ﬁnding suggests that, irrespective of location,
collaterals, or noninvasive imaging, most CTOs are
ischemic.
Percutaneous revascularization of CTOs signiﬁ-
cantly decreased the ischemic burden (assessed by
quantitative noninvasive imaging) from 13.1% to
6.9% (11). The majority of patients had moderate to
severe ischemic burden ($10% ischemic myocardium)
at baseline. The risk of future adverse cardiac
events, as related to baseline ischemic burden,
and clinical beneﬁts of reduced ischemic burden
post-revascularization, remains under investigation.
A nuclear imaging study in coronary artery patients
suggested that there was improved survival following
revascularization (PCI or CABG) only in the presence
of moderate to severe baseline ischemic burden
($10% ischemic myocardium) (12). A COURAGE
(Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) nuclear substudy also
reported signiﬁcant angina class improvements
following percutaneous revascularization in patients
with baseline moderate to severe ischemic burden
($10% ischemic myocardium), with subsequent im-
provements of >5% (13). Additional studies are
required in the speciﬁc CTO subgroup.
DO PATIENTS WITH CTO HAVE SYMPTOMS?
Clinicians should be aware of several unique features
of CTOs. Anecdotal experience suggests that typical
anginal chest pain symptoms may be less prominent
than shortness of breath; thus, physicians may un-
derestimate symptom severity. Additional evidence
pertaining to a CTO’s impact on patient symptoms is
provided by studies on patient-reported QOL.
In the past 3 years, several studies reported broad
patient improvements in QOL indexes (an important
criterion in developing the AUC guideline) following
successful CTO revascularization. Three studies
compared PCI treatment in CTO, and 1 compared
successful CTO revascularization (by either surgery or
PCI) to medical therapy (14–17). Beneﬁcial effects of
CTO recanalization on QOL included less physical
activity limitation (p ¼ 0.01), rarer angina episodes
(p < 0.001), and greater treatment satisfaction
(p ¼ 0.03) compared with patients with failed pro-
cedures (15). Symptoms, function, QOL, and dyspnea
improved to the same degree following CTO PCI as
following non-CTO PCI (14).A recent multicenter, prospective cohort study
evaluated QOL at 1 year in CTO patients who under-
went 1 of the following 4 treatment options: medical
therapy, PCI to non-CTO, PCI to CTO, and CABG (17).
Medically-treated patients did not improve. Patients
with CTO territory revascularization with either PCI
or CABG had signiﬁcant improvements in physical
limitation (PCI to CTO: 60.5 to 76.4; CABG: 61.6 to
80.1; p < 0.001), angina frequency (PCI to CTO: 79.0
to 92.7; CABG: 82.1 to 97.9; p < 0.001), and disease
perception (PCI to CTO: 50.5 to 75.0; CABG: 50.2 to
80.0; p < 0.001) domains. These studies suggest that
CTO patients are often limited by their symptoms
and, importantly, experience improvement with
revascularization.
CAN CTOs BE RELIABLY OPENED BY PCI? Histori-
cally, PCI procedural success for CTOs ranged from
70% to 75% (18). Advanced CTO techniques and
equipment, along with increasing operator experi-
ence, signiﬁcantly enhanced success rates of percu-
taneous CTO revascularization. The Euro CTO club
reported an overall procedural success rate of almost
83% in the ERCTO (European Registry of Chronic
Total Occlusion) (19). Recent publications suggest
that very experienced and expert operators have even
higher success rates. Successful percutaneous revas-
cularization at the Toyohashi Heart Center recently
increased to 90% from around 80% in 2002. Overall
procedural success was achieved in 780 (86.2%)
lesions (20). Thompson et al. (21) reported that the
success rate of dedicated CTO operators increased to
90% over time (94.4% for retrograde and 85.7% for
antegrade approaches). The Multicenter CTO Registry
of Japan also reported higher success rates with
additional experience: 68.4% to 88.1% in difﬁcult
cases, and 42.0% to 78.9% in very difﬁcult cases
(22). Similarly, the FAST-CTOs (Facilitated Antegrade
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using the Crossboss catheter and stingray balloon
re-entry system (Boston Scientiﬁc, Marlborough,
Massachusetts) had a 67% success rate in the ﬁrst
75 CTOs, increasing to 87% in the last 75 (23). It is
difﬁcult to know whether these expanded skill sets
signiﬁcantly impact the overall number of CTOs
attempted. It is also unclear if the frequency of CTO
PCI procedures can substantially increase while
remaining the CTO expert’s domain.
IS A CTO PROCEDURE MORE RISKY? Lone CTOs
are typically addressed by PCI (Table 1). Complica-
tion rates are decreasing, although they are higher
than non-CTO revascularization. A meta-analysis
of 65 CTO PCI studies performed between 2000
and 2011 reported 77% angiographic success, with
low periprocedural complication rates: 0.2% death,
2.5% myocardial infarction (MI), 0.1% emergent
CABG, <0.01% stroke, and 2.9% coronary perforation,
with 0.3% cardiac tamponade (24). Although coronary
perforation is a serious PCI complication, occurring
more frequently in CTO than in non-CTO PCI pro-
cedures, it is relatively rare and generally requires no
speciﬁc intervention or need for bypass surgery (25).
However, the true complication rates of CTO PCI
in routine practice may not be reﬂected in publi-
shed reports (predominantly from experienced oper-
ators and sites), and may not be representative of
lower-volume operators. More complex techniques
(e.g., the retrograde approach or subintimal tracking
devices) enable successful revascularization in the
most complex group of CTOs, but carry an increased
risk of complications compared with more conven-
tional anterograde guidewire strategies.
The highly experienced, dedicated European CTO
PCI operators who contributed to the ERCTO registry
reported a higher complication rate with the retro-
grade approach. Coronary perforation occurred in
4.7% of procedures, compared with 2.1% in the
anterograde approach (p¼ 0.04). Retrograde approach
procedures were longer, with higher ﬂuoroscopy
times and larger contrast load administration, and
were associated with increased rates of non–Q-wave
MI at 30 days, (2.1% vs. 1%; p ¼ 0.08) (19). A meta-
analysis of 3,482 patients from 26 studies who un-
derwent a retrograde approach reported an overall
success rate of 83.3%, lower than non-CTO PCI. Major
adverse cardiac event (MACE) rates (0.7% death, 0.7%
urgent CABG, 3.1% MI, and 0.5% stroke) with the
retrograde approach were low, although collateral
vessel perforations were still common (6.9%), with
4.3% coronary perforation and 1.4% cardiac tampo-
nade (26). Other negative consequences of CTO PCIinclude increased radiation exposure and high
contrast loads related to prolonged procedures.
SUMMARY OF LONE CTO. Patients with lone CTO
often have atypical, yet functionally limiting, symp-
toms with substantial ischemia. Recent history sug-
gests that complex PCI procedures have improved
success and relatively low risks, albeit still below
the levels of non-CTO PCI. The critical caveat to
expanding PCI therapy for “appropriate” CTOs is that
the primary basis of published statistics is the expe-
rience of interventionalists with speciﬁc CTO training
and procedure volumes.
CTOs IN MULTIVESSEL DISEASE
CTO is more common in the presence of other
signiﬁcantly-narrowed coronary arteries. In the
Canadian CTO Registry (4), multivessel CAD (>50%
diameter stenosis) was present in three-fourths of
patients with CTOs, and revascularization frequency
and modality differed according to the disease’s
extent (Table 1). In single-vessel disease, PCI was
performed 4-fold more frequently than CABG,
although overall CTO revascularization was only 21%.
In 2-vessel disease, both CTO revascularization pro-
cedures were performed equally (approximately
10% each). For 3-vessel disease (the largest group,
accounting for >60% of the registry), CABG was the
overwhelming CTO vessel revascularization modal-
ity, performed 3-fold more often than PCI (22% vs.
7%). In patients with 2- and 3-vessel disease under-
going percutaneous revascularization, the CTO artery
was attempted in only 22% of cases (Table 1). Thus,
current clinical practice for percutaneous treatment
of multivessel disease (including CTO) is to perform
PCI in nonoccluded vessels, leaving the CTO unre-
vascularized (incomplete revascularization [IR]). We
will examine the rationale for CTO revascularization
as part of a complete revascularization (CR) strategy.
CR VERSUS IR. CR may be deﬁned on the basis of
anatomy, extent of ischemia, and other criteria (27).
The most accepted deﬁnition is simply successful
treatment of all major epicardial coronary vessels by a
revascularization modality, either bypass surgery or
percutaneous revascularization (27). A summary of
studies and registries comparing CR and IR can be
found in Table 2.
Surg ica l versus medica l s tud ies . Many published
studies on surgical coronary bypass show the impor-
tance of CR for long-term outcome, including survival
beneﬁts (28,29). As early as the 1970s, CR was evalu-
ated in the registry of nonrandomized patients
treated surgically from CASS (Coronary Artery
TABLE 2 Completeness of Revascularization and CTOs in Multivessel Revascularization Trials and Registries
Trial, Years (Ref. #) Patients, n Design CTO in Trial Impact of CR
CASS, 1974–1979 (28) 3,372 Registry of nonrandomized
surgical cohort
NA YMortality in patients with either
severe angina or ejection
fraction <35%
MASS-II, 1995–2000 (30,31) 611 Randomization to CABG,
PCI, or medical therapy
NA PCI arm: CR in 41%.
YCardiovascular mortality in CR.
Survival 90.6% in CR vs. 84.4% IR
(p ¼ 0.04)
BARI, 1988–1991 (32) 1,829 Randomization to PCI
or CABG
60% excluded due to PCI
unsuitability of 8,000
screened
No differences
ERACI II, 1996–1998 (34) 450 Randomization to PCI
or CABG
PCI not attempted in
CTOs (23.4%)
No data on CR.
YMACE in CABG (Freedom from
MACE 76.4% in CABG vs.
65.3% in PCI; p ¼ 0.013).
SoS, 1996–1999 (35) 988 Randomization to PCI
or CABG
CTOs excluded from trial No data on CR.
YMortality in CABG compared
with PCI (6.8% vs.10.9%)
SYNTAX, 2005–2007
(37,39,40)
1,800 3-vessel disease or left
main disease;
randomization to PCI
or CABG
23% YCR in high and intermediate
syntax scores.
[CR with CABG.
[Cardiac mortality with high
syntax score at 1 yr and
intermediate at 3 yrs
New York State PCI Reporting
System, 1997–2000 (43)
21,945 PCI registry NA [Mortality (adjusted hazard ratio:
1.35) in IR patients compared
with CR in the presence of
either a single IR CTO or $2 IR
vessels
BARI ¼ Bypass Angioplasty Revascularization Investigation; CASS ¼ Coronary Artery Surgery Study; CR ¼ complete revascularization; ERACI ¼ Argentine Randomized Trial of
Coronary Angioplasty With Stenting Versus Coronary Bypass Surgery in Patients With Multiple Vessel Disease; IR ¼ incomplete revascularization; MACE ¼major adverse cardiac
events; MASS ¼ Medicine, Angioplasty, or Surgery Study; SoS ¼ Stent or Surgery; SYNTAX ¼ Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac
Surgery; other abbreviations as in Table 1.
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bypass surgery versus medical therapy. Patients with
severe angina who underwent CR had improved sur-
vival and cardiac events (death, MI, reoperation, and
deﬁnite angina). The patient subgroup with ejection
fraction <35% also showed this survival beneﬁt, even
without severe angina (28).
Surgery versus PCI stud ies . The CR rate was
consistently and signiﬁcantly lower in the PCI arms of
multivessel trials published in the 1990s. MASS-II
(Medicine, Angioplasty, or Surgery Study) was a ran-
domized, controlled clinical trial of medical therapy,
PCI, or CABG for multivessel CAD. In the PCI arm,
immediate angiographic success was achieved in 92%
of patients; however, CR was achieved in only 41%
(30). The reason(s) for low CR rates in the PCI arm
were not revealed, including CTO prevalence and
revascularization. Over the 10-year follow-up, CR was
associated with reduced cardiovascular mortality
compared with IR, especially due to a greater increase
in cardiovascular-speciﬁc mortality in PCI-treated
patients (31).
Few CTO lesions were included in these compara-
tive studies. In the BARI (Bypass Angioplasty Revas-
cularization Investigation), CTOs were present in 68%
of 8,000 patients and were the main angiographicreason patients were deemed unsuitable for PCI
(32). Other studies almost completely excluding CTO
patients include ARTS (Arterial Revascularization
Therapies Study) I and II, in which only 3% of lesions
were American Heart Association type C (including
CTOs) (33). In the ERACI II (Argentine Randomized
Trial of Coronary Angioplasty With Stenting Versus
Coronary Bypass Surgery in Patients With Multiple
Vessel Disease), angioplasty was not attempted in
CTOs (23.4%); therefore, CR was more frequently
achieved with CABG than with coronary angioplasty
(85% vs. 50.2%, respectively) (34). The SoS (Stent or
Surgery) trial only recruited patients suitable for both
PCI and CABG, excluding many CTO cases (35).
CR’s critical importance was reinforced by meta-
analysis of CR versus IR in patients with multivessel
CAD (36). CR was more often achieved with CABG
than with PCI, and was associated with 30% reduction
in long-term mortality, 22% reduction in MI, and 26%
reduction in repeat coronary revascularization pro-
cedures. In these major clinical trials, percutaneous
interventions were frequently incomplete due to
several factors, but particularly failed CTO revascu-
larization (other factors included a decision to treat
only the culprit artery or patient factors such as poor
LV function, elevated creatinine, or frailty).
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onary Intervention with Taxus and Cardiac Surgery)
trial randomized 1,800 patients with either 3-vessel
or left main disease to bypass surgery or PCI. CTOs
were common, with an overall 23% prevalence in
SYNTAX study patients (37). In the SYNTAX trial,
coronary anatomy complexity on diagnostic angio-
grams was graded by a Syntax score algorithm (38),
with patients divided into high-, intermediate-, or
low-score groups. The Syntax score highly depended
on the presence and speciﬁc features of CTO, with a
single CTO contributing a substantial 10 to 15 points.
Although relatively low in both treatment groups,
successful CTO revascularization was much higher in
bypass surgery (69%) than PCI (49%), possibly
contributing to differences in MACE including mor-
tality between the 2 revascularization strategies (5).
The most common reason for not achieving CR with
PCI was the presence of a CTO (odds ratio: 2.46, 95%
conﬁdence interval: 1.66 to 3.64; p < 0.001) (39).
Generally, the Syntax score, a surrogate marker for
disease complexity, was higher in IR than in CR pa-
tients (31.4  11 vs. 26.2  10; p < 0.01) (39). Thus, CTO
lesions were over-represented in the high Syntax
score group, with vastly inferior revascularization
success rates in the PCI group. Indeed, procedural
success of CTO revascularization with PCI in the
SYNTAX study was <50%, highlighting insufﬁcient
CTO operator expertise for these complex lesions. In
contrast, PCI or CABG procedural success rates in
patients with lower SYNTAX scores were very similar,
with minor outcome differences between the 2 mo-
dalities. MACE (death, cerebrovascular accident, MI,
repeat vascularization) and even cardiac mortality
were signiﬁcantly worse in PCI patients with a high
Syntax score (>32 points). These differences were
evident at the 1-year data analysis and were even
more pronounced at 3 years (including the interme-
diate Syntax score of 23 to 32 points) (40).
Residual Syntax score is derived from the extent
and complexity of residual coronary disease after PCI,
and represents an assessment of completeness of
revascularization. In the SYNTAX trial, a residual
Syntax score >8 signiﬁcantly increased mortality
(35.3%) at 5 years (41). More recently, Syntax scoring
for predicting IR rates and clinical outcomes was used
in a reanalysis of 2,686 angiograms from ACUITY
(Acute Catheterization and Urgent Intervention
Triage strategY) trial PCI patients (42). CR’s impor-
tance was again supported by higher 1-year ischemic
event rates in the IR group compared with the CR
group, particularly with a high residual Syntax score.
These data reinforce the potential importance of CR,
with CTO as the major barrier.PCI reg ist r ies . The New York State Percutaneous
Coronary Intervention Reporting System provided
additional evidence supporting CTO revasculariza-
tion as key to achieving CR (43). Hannan et al. (43)
subdivided 22,000 patients with multivessel disease
undergoing revascularization by PCI into CR (31%)
and IR (69%). Mortality was signiﬁcantly increased
(adjusted hazard ratio: 1.35) in IR patients compared
with CR in the presence of either a single IR CTO
or $2 IR vessels (43). A PCI registry study using the
large APPROACH (Alberta Provincial Project for Out-
comes Assessment in Coronary Heart Disease) data-
base similarly showed the association of CTOs with IR
and a reduction in death and need for future bypass
surgery in patients with CR compared with IR (44).
VIABILITY IN MULTIVESSEL DISEASE. Patients with
multivessel disease often have LV dysfunction, in
some cases remaining viable, and thus potentially
reversible (45). The term hibernating myocardium
describes “a state of myocardial hypocontractility
during chronic hypoperfusion, in the presence of
completely viable myocardium which recovers func-
tionally upon revascularization” (46). Hibernating
myocardium is associated with LV dimension and
shape alterations that signiﬁcantly revert after
revascularization (47). Accordingly, viability testing
utilizing a variety of imaging techniques, in-
cluding dobutamine stress echocardiography, single-
photon emission computed tomography nuclear
scintigraphy, contrast-enhanced cardiac magnetic
resonance (CMR), and positron emission tomography,
is crucial for evaluating the potential revasculariza-
tion treatment beneﬁt (48,49). Several studies
showed beneﬁcial effects of CTO revascularization on
abnormal LV geometry and function if the CTO artery
supplies viable myocardium (50,51). CTO revascular-
ization beneﬁts were related to the transmural extent
of infarction; PCI only improved segmental contrac-
tility in areas where transmurality of infarction
was <75%, with no effect with higher extent of
infarction (52). These beneﬁcial effects were observed
up to 3 years after recanalization (53,54). No data
speciﬁcally address the relationship between viability
and clinical outcomes in CTO patients; however,
several small observational studies and 2 randomized
trials addressed this question (55–58). In a study of
144 patients with CAD and LV dysfunction by CMR,
survival was improved in patients with viable
myocardium that was subsequently revascularized,
compared with nonrevascularized patients. There
was no signiﬁcant difference in survival in patients
with nonviable myocardium, irrespective of revascu-
larization (59).
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trials—PARR-2 (PET and Recovery Following Revas-
cularization Phase 2) using positron emission to-
mography imaging and the STICH (Surgical Treatment
for Ischemic Heart Failure) Viability Substudy using
thallium scintigraphy—showed no signiﬁcant effects
of viability assessment on clinical outcomes following
revascularization (57,58). However, their interpreta-
tion is challenged by signiﬁcant methodological
ﬂaws, including low adherence to image-guided rec-
ommendations, baseline patient differences, post-
hoc subgroup analyses, revascularization not guided
by the presence of viable myocardium, and small size
of the nonviable myocardium group (60). Further
studies are essential to provide reliable data for
assessing the requirement for viability testing in pa-
tients with LV dysfunction to guide revascularization
strategies, particularly in CTOs.
AUC AND CTO IN MULTIVESSEL DISEASE. The AUC
for coronary revascularization 2012 update highlights
CTOs as important contributors to “intermediate to
high” CAD burden in patients with 3-vessel disease.
The AUC differentiates the revascularization modality
for CTOs in the setting of multivessel disease, with an
AUC rating of “appropriate” for surgical revasculari-
zation and “uncertain” for PCI (and, in LM þ 3-vessel
disease, “appropriate” for CABG and “inappropriate”
for PCI) (7). This reﬂects the fact that successful PCI
performance in CTO is difﬁcult for most PCI physi-
cians. However, procedural success and safety highly
depend upon the operator’s experience; thus, this
rating should be interpreted in the context of whether
a CTO expert performed the procedure.
THE FUTURE OF CTO REVASCULARIZATION
Many studies and several meta-analyses compared
patient outcomes with successful and failed PCI CTO,
consistently ﬁnding improved outcomes with suc-
cessful procedures. Khan et al. (61) evaluated 23
observational studies comparing clinical outcomes
between patients with successful CTO recanalization
and those managed conservatively as a result of failed
PCI. Successful CTO PCI was signiﬁcantly associated
with improved all-cause mortality (relative risk:
0.54), and lower MACE rates (relative risk: 0.70)
(61). Similarly, a meta-analysis of 13 observational
studies found that, compared with unsuccessful PCI,successful PCI is associated with improved mortality
and reduced need for CABG (62). These studies (and
the majority of studies cited in this review) are
observational and are thus prone to confounding.
There is a lack of robust type A evidence with hard
clinical outcomes on the beneﬁts of CTO revasculari-
zation. Several trials expected to advance these dis-
cussions are currently underway or in advanced
planning stages. The EXPLORE (Evaluating Xience V
and LV function in Percutaneous coronary interven-
tion on occLusiOns afteR ST-Elevation myocardial
infarction) trial, a randomized study in the ﬁnal
enrollment stages, addresses whether revasculariza-
tion of a CTO nonculprit artery in patients presenting
with ST-segment elevation MI will be beneﬁcial for LV
function at 4 months. DECISION-CTO (Drug-Eluting
Stent Implantation versus Optimal Medical Treat-
ment in Patients with Chronic Total Occlusion) is a
randomized trial to compare the long-term (3-year)
outcome of drug-eluting stent implantation with
optimal medical treatment. EURO-CTO (European
Study on the Utilization of Revascularization vs.
Optimal Medical Therapy for the Treatment of
Chronic Total Coronary Occlusions) is a multicenter
trial to evaluate 1- and 3-year outcomes and assess
QOL in patients randomized to revascularization or
optimal medical therapy.
CONCLUSIONS
The therapeutic nihilism often associated with
revascularization in CTO has been plagued by mis-
conceptions as to the degree of symptoms and
ischemia caused, and the potential beneﬁt of revas-
cularization. Over the last few years, evidence is
increasing that CTO lesions have substantial impact
and should be held to similar criteria as nonocclusive
lesions. We are optimistic that new studies with
compelling data will assist clinicians and the AUC
guidelines writing groups to more judiciously deter-
mine CTO revascularization indications.
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